A detailed history of Mv Capital Management, Inc. transactions in Incyte Corp stock. As of the latest transaction made, Mv Capital Management, Inc. holds 109 shares of INCY stock, worth $7,744. This represents 0.0% of its overall portfolio holdings.

Number of Shares
109
Previous 131 16.79%
Holding current value
$7,744
Previous $7,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$57.33 - $68.61 $1,261 - $1,509
-22 Reduced 16.79%
109 $7,000
Q2 2024

Aug 01, 2024

BUY
$51.18 - $63.75 $409 - $510
8 Added 6.5%
131 $7,000
Q1 2024

Apr 18, 2024

SELL
$56.55 - $66.59 $113 - $133
-2 Reduced 1.6%
123 $7,000
Q4 2023

Jan 29, 2024

BUY
$52.16 - $64.19 $1,982 - $2,439
38 Added 43.68%
125 $7,000
Q3 2023

Nov 07, 2023

SELL
$57.77 - $65.93 $4,563 - $5,208
-79 Reduced 47.59%
87 $5,000
Q2 2023

Aug 03, 2023

SELL
$60.95 - $75.51 $4,083 - $5,059
-67 Reduced 28.76%
166 $10,000
Q1 2023

Apr 26, 2023

BUY
$70.23 - $86.01 $1,755 - $2,150
25 Added 12.02%
233 $16,000
Q4 2022

Jan 27, 2023

SELL
$67.18 - $84.11 $268 - $336
-4 Reduced 1.89%
208 $0
Q3 2022

Oct 24, 2022

BUY
$66.18 - $82.86 $463 - $580
7 Added 3.41%
212 $14,000
Q2 2022

Jul 19, 2022

SELL
$66.18 - $83.18 $66 - $83
-1 Reduced 0.49%
205 $16,000
Q1 2022

May 09, 2022

BUY
$66.02 - $79.71 $3,433 - $4,144
52 Added 33.77%
206 $16,000
Q4 2021

Feb 02, 2022

BUY
$63.34 - $74.11 $8,550 - $10,004
135 Added 710.53%
154 $11,000
Q3 2021

Nov 12, 2021

SELL
$68.67 - $84.02 $1,373 - $1,680
-20 Reduced 51.28%
19 $1,000
Q2 2021

Aug 03, 2021

BUY
$79.87 - $87.53 $3,114 - $3,413
39 New
39 $3,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.8B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Mv Capital Management, Inc. Portfolio

Follow Mv Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mv Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mv Capital Management, Inc. with notifications on news.